Skip to main content
    T

    TG Therapeutics Inc (TGTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $62.76
    -1.75 (-2.71%)

    Market Cap: $9.75B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    TG Therapeutics Inc (TGTX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    TG Therapeutics (TGTX) trades at 87.2x trailing earnings and 11.1x sales. Its P/S of 11.1x is below its 5-year median of 13.2x. Its forward P/E is 29.9x. The median P/E across 3 similar companies is 39.6x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 191.6% higher over the next year. Its free cash flow yield is 0.2%.

    MultipleValue
    P/E (trailing)87.2x
    Forward P/E29.9x
    Price to sales11.1x
    Price to book14.7x
    EV/EBITDA61.9x
    Price to FCF511.8x
    EV/FCF526.9x
    PEG1.6
    FCF yield0.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 23.5% above 11.9x.

    MultipleCurrent5-year median10-year median
    P/S11.1x13.2xN/A
    P/B14.7x13.5x11.9x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 114 months (10-year).

    Valuation History

    Over the 5 of the 10 year ends shown that have a P/S, its P/S ranged from 7.3x in 2025 to 571.7x in 2022. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$29.8159.6x7.3x7.3x
    2024$30.10215.0x13.7x21.7x
    2023$17.08N/A10.4x15.2x
    2022$11.83N/A571.7x27.7x
    2021$19.00N/A375.8x10.6x
    2020$52.02N/AN/A12.4x
    2019$11.10N/AN/A27.5x
    2018$4.10N/AN/A13.8x
    2017$8.20N/AN/A8.1x
    2016$4.65N/AN/A6.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TGTX

    What is TGTX's forward P/E ratio?

    TG Therapeutics has a forward P/E ratio of 29.9x.

    Is TGTX stock overvalued?

    GNG's valuation label for TGTX is Fairly valued. Its P/E of 87.2x compares with a median of 39.6x across 3 similar companies.

    What is TGTX's price to sales ratio?

    TG Therapeutics has a price to sales ratio of 11.1x.

    What is TGTX's PEG ratio?

    TG Therapeutics has a PEG ratio of 1.6.